Alerta

新型细胞因子组合mRNA疫苗佐剂及其应用

Resumen de: CN120733023A

本发明提供了一种新型细胞因子组合mRNA疫苗佐剂及其应用，所述疫苗佐剂包括可电离脂质、胆固醇、磷脂、PEG衍生物，以及含有编码GM‑CSF和IL‑21基因序列的mRNA；其中，GM‑CSF和IL‑21的氨基酸序列分别如SEQ ID NO:1、2所示。将本发明所述新型细胞因子组合mRNA疫苗佐剂应用于疫苗的制备，组合的细胞因子在注射部位对DC的招募和调控促进了LNP递送和表达引发了强烈的抗肿瘤效应。具体的，通过协同作用通过对注射部位免疫微环境的建立提升了抗原被表达、识别和呈递并且促进了抗原的交叉提呈，DC细胞的激活和淋巴结的浸润促进了T细胞的活化，为肿瘤免疫治疗建立了强大了抗肿瘤效应和免疫记忆。

一种生物合成虾青素的马氏副球菌及其色素提取物和应用

Resumen de: CN120738011A

本发明公开了一种生物合成虾青素的马氏副球菌及其色素提取物和应用。该马氏副球菌（Paracoccus marcusii）IHA069于2022年7月15日保藏于中国普通微生物菌种保藏中心，保藏编号为CGMCC No.25302，16s rDNA序列如SEQ ID No.1所示。通过发酵培养基培养48h后，离心并采用无水乙醇萃取菌体得到色素提取物，虾青素在色素提取物中的比例达到40%。马氏副球色素提取物为主料，玉米淀粉、吐温‑80、氯化钙水为配料，调和喷雾干燥得到具有抗氧化效果的纳米颗粒。相较于IHA034，IHA069强化了提高了虾青素产量便于工业生产，提高了在不同动物中使用的可行性。本发明采用纳米颗粒包埋技术提高了色素提取物中虾青素的保留率，提高了保存温度和有效时间。

一种用于金黄色葡萄球菌感染检测灭活的诊疗探针

Resumen de: CN120733070A

本发明公开了一种用于金黄色葡萄球菌感染检测灭活的诊疗探针，构建方法包括：S1：双波长激发量子点的制备；S2：量子点@ZIF‑8的制备，在量子点表面进行PSS修饰，后在ZIF‑8包覆过程中在1小时内匀速缓慢滴加2‑甲基咪唑溶液用以控制纳米颗粒的成核速率，并且加入PVP稳定纳米粒子的形成；S3：量子点@ZIF‑8@Ber的制备，在合成过程中将小檗碱加入溶剂中，采用一锅法直接合成得到负载小檗碱的量子点@ZIF‑8材料。本发明利用夹心法对金黄色葡萄球菌进行检测，结果通过荧光检测仪反馈，并且可以连接手机进行智能化监测，简便快捷；利用抗原抗体反应，靶向捕获金黄色葡萄球菌，其余细菌的影响很小。

一种氨基酸阳离子脂质

Resumen de: CN117460710A

The invention provides a novel amino acid cationic lipid, the structure of which is shown in a general formula (1), and the definition of each symbol is consistent with that described in the specification. The amino acid cationic lipid is a pharmaceutically acceptable, biodegradable or high-biocompatibility lipid, and has the advantages of low toxicity, low immunogenicity and high biocompatibility. The amino acid or the amino acid derivative used in the preparation process is simple and easy to obtain, can be naturally obtained or simply synthesized, and has the advantages of simplicity, convenience, safety and production cost saving. Degradable groups can further be contained between amino acid residues and lipophilic tail chains of the novel amino acid cationic lipid, due to existence of the degradable groups, lipid nanoparticles LNP prepared from the novel amino acid cationic lipid can be degraded in vivo in good time, and the problems that in the prior art, LNP prepared from lipid which cannot be degraded can be stored in vivo, the endosome environment is acidified, and the lipid nanoparticles LNP cannot be degraded in vivo are solved. Endosome escape of drug molecules (such as nucleic acid) is blocked, and the problem that drugs delivered into cells cannot play a role is solved. # imgabs0 #

一种用于治疗急性呼吸窘迫综合征的仿胞葬纳米制剂

Resumen de: CN120732785A

本发明公开了一种用于治疗急性呼吸窘迫综合征的仿胞葬纳米制剂，属于生物医药技术领域。本发明的仿胞葬纳米制剂包括活性成分、脂质体磷脂双分子层和靶头，所述活性成分由ROS清除药物和抗炎药物组成。本发明创新性地运用仿胞葬作用实现纳米制剂的高效精准靶向，在脂质体表面修饰凋亡细胞标志物，通过释放“eat me”信号，模拟巨噬细胞清除凋亡细胞的天然生物学过程被肺泡巨噬细胞识别并吞噬，实现高效特异性靶向，同时炎症部位巨噬细胞PS受体表达上调进一步增强了靶向效果，为急性呼吸窘迫综合征药物制剂高效递送及病理微环境的重塑提供了一种新的途径。

一种氨基酸阳离子脂质

Resumen de: CN117460710A

The invention provides a novel amino acid cationic lipid, the structure of which is shown in a general formula (1), and the definition of each symbol is consistent with that described in the specification. The amino acid cationic lipid is a pharmaceutically acceptable, biodegradable or high-biocompatibility lipid, and has the advantages of low toxicity, low immunogenicity and high biocompatibility. The amino acid or the amino acid derivative used in the preparation process is simple and easy to obtain, can be naturally obtained or simply synthesized, and has the advantages of simplicity, convenience, safety and production cost saving. Degradable groups can further be contained between amino acid residues and lipophilic tail chains of the novel amino acid cationic lipid, due to existence of the degradable groups, lipid nanoparticles LNP prepared from the novel amino acid cationic lipid can be degraded in vivo in good time, and the problems that in the prior art, LNP prepared from lipid which cannot be degraded can be stored in vivo, the endosome environment is acidified, and the lipid nanoparticles LNP cannot be degraded in vivo are solved. Endosome escape of drug molecules (such as nucleic acid) is blocked, and the problem that drugs delivered into cells cannot play a role is solved. # imgabs0 #

编码治疗性多肽的核酸及包含所述核酸的脂质纳米颗粒组合物

Resumen de: WO2024199114A1

Provided are lipid nanoparticle compositions comprising nucleic acids encoding RSV antigenic polypeptides. Also provided are novel antigenic RSV-F polypeptides as well as nucleic acids encoding the antigenic RSV-F polypeptides.

一种基于Mn-DNA纳米疫苗的肿瘤免疫治疗方法

Resumen de: CN120733013A

本发明涉及一种基于Mn‑DNA纳米疫苗的肿瘤免疫治疗方法。本发明提供一种用于肿瘤免疫治疗的纳米颗粒，其包含金属离子Mn2+、外源dsDNA、抗原肽和打靶肽。本发明还提供制备所述纳米颗粒的方法、包含所述纳米颗粒的疫苗或药物组合物以及它们用于肿瘤免疫治疗的用途等。本发明的纳米颗粒能够被精准递送到抗原提呈细胞，促进抗原提呈细胞成熟，增强抗原递呈能力，显著增强肿瘤靶向性和抗肿瘤活性。本发明所用原料在体内均可降解，生物安全性高。

一种具有肿瘤能量代谢调控功能的自组装基因纳米药物及其制备方法和应用

Resumen de: CN120733055A

本发明公开了一种具有肿瘤能量代谢调控功能的自组装基因纳米药物及其制备方法和应用，属于纳米材料技术领域。本发明通过将光敏剂与阳离子聚合物偶联，形成基因递送载体，该复合物在特定光照条件下能够增强肿瘤细胞的凋亡效果；通过将光敏剂与siRNA结合，实现了多重治疗机制的协同作用，不仅能精准靶向肿瘤细胞并干预其能量代谢，还能在光照下增强细胞死亡效应，显著提高治疗效果。本发明通过靶向肿瘤细胞中高表达的与能量代谢相关的基因，并结合光动力疗法，解决了现有技术在肿瘤能量代谢干预方面的不足，有望在未来成为靶向细胞器的新型治疗手段，可用于抗癌、抗菌、抗炎等药物治疗及示踪。

经由穿膜肽进行非共价修饰脂质纳米颗粒缀合物及用途

Resumen de: CN120737148A

本发明提供了一种多肽衍生物，其具有结构式CnH2n+1CONH‑CPP‑COOH，其中，n=11，13，15，17；CPP为穿膜肽。本发明还提供了该多肽衍生物的制备方法和与脂质纳米颗粒缀合的用途。本发明通过加入在LNP配方中加入基于CPP的阳离子两亲性分子，由可电离脂质负责mRNA的内体释放而CPP促进LNP与细胞膜的结合，通过调整各组分组成比例以及电荷，显著提升了LNP在体内外的递送效率，经由TAT序列修饰LNP可使得肝脏体内递送效率提升20倍。

一种氨基酸阳离子脂质

Resumen de: CN117460710A

The invention provides a novel amino acid cationic lipid, the structure of which is shown in a general formula (1), and the definition of each symbol is consistent with that described in the specification. The amino acid cationic lipid is a pharmaceutically acceptable, biodegradable or high-biocompatibility lipid, and has the advantages of low toxicity, low immunogenicity and high biocompatibility. The amino acid or the amino acid derivative used in the preparation process is simple and easy to obtain, can be naturally obtained or simply synthesized, and has the advantages of simplicity, convenience, safety and production cost saving. Degradable groups can further be contained between amino acid residues and lipophilic tail chains of the novel amino acid cationic lipid, due to existence of the degradable groups, lipid nanoparticles LNP prepared from the novel amino acid cationic lipid can be degraded in vivo in good time, and the problems that in the prior art, LNP prepared from lipid which cannot be degraded can be stored in vivo, the endosome environment is acidified, and the lipid nanoparticles LNP cannot be degraded in vivo are solved. Endosome escape of drug molecules (such as nucleic acid) is blocked, and the problem that drugs delivered into cells cannot play a role is solved. # imgabs0 #

一种脂质纳米颗粒及其应用

Resumen de: CN120732814A

本发明涉及一种脂质纳米颗粒及其应用。所述脂质纳米颗粒包括：阳离子脂质、阴离子脂质DOPS（1,2‑二油酰基‑sn‑甘油‑3‑磷脂酰‑L‑丝氨酸）、其他脂质和靶向抗体。本发明经过研究发现，掺杂阴离子脂质DOPS并间接偶联靶向抗体可以显著提高纳米颗粒对脾脏T细胞的转染效率。本发明进一步将编码靶向肿瘤血管内皮细胞和肿瘤细胞的CAR蛋白的核酸装载在上述脂质纳米颗粒中并用于肿瘤治疗，结果上述治疗显著促进了免疫细胞的瘤内浸润，显著抑制多种实体瘤进展，为CAR‑T疗法在实体瘤中的有效应用提供了新思路、新手段。

LIPID COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF

Resumen de: WO2025207803A1

Described are compounds, compositions, and methods for delivery of therapeutic, diagnostic, or prophylactic agents (for example, a nucleic acid).

NOVEL LIPID BASED ON OLIGO-GAMMA-GLUTAMIC ACID DERIVATIVE, LIPID NANOPARTICLES COMPRISING SAME, AND USE THEREOF

Resumen de: WO2025206461A1

The present invention relates to a novel lipid derivative compound comprising an oligo-gamma-glutamic acid, a lipid nanoparticle composition comprising the same, and the like. According to the present invention, the compound can form lipid nanoparticles by replacing PEGylated lipids, and thus can prevent side effects such as anaphylaxis and has excellent in vivo stability.

MICROPROJECTION ARRAYS

Resumen de: WO2025199580A1

The present invention relates to formulations, devices and methods for coating surfaces of microprojections on microprojection arrays with nucleic acids. The present invention also relates to formulations and methods for coating surfaces of microprojections with nucleic acids where the nucleic acids are associated with lipid nanoparticles (LNP), in particular where the nucleic acid is mRNA.

POLYMERS FOR ENHANCING LIPID NANOPARTICLE DELIVERY OF NUCLEIC ACIDS

Resumen de: WO2025207986A1

The present invention provides delivery-enhancing polymers capable of being encapsulated in nanoparticles to enhance release of payload from the nanoparticle wherein the delivery-enhancing polymer comprises a polyamine comprising tertiary amine. The delivery-enhancing polymer may comprise methylated polyethylenimine (mPEI), branched PEI (bPEI), PAMAM dendrimer and/or histidine polymer.

CELL THERAPY

Resumen de: WO2025206323A1

The present disclosure provides a novel modality for a new target disease (e.g. pancreatic cancer). The present disclosure applies a mRNA CAR-T vaccine to CAR-T for a new target disease (e.g., pancreatic cancer). In the present disclosure, it has been revealed, by in vitro and in vivo experiments, that a mRNA CAR-T vaccine that targets FAP as an antigen can achieve a potent anti-tumor effect in in vivo editing. As for a mechanism for inhibiting the effect of a mRNA CAR-T vaccine, the pathways involving regulatory T cells and the like have also been revealed. As for a synergistic effect with an immune checkpoint agonist, a "condition" for achieving a potent anti-tumor effect in vivo has also been revealed through much trial and error.

FORMULATIONS FOR ADMINISTERING LAAM, norLAAM AND dinorLAAM AND METHODS OF THEIR USE TO TREAT OPIOID USE DISORDER

Resumen de: US2025302751A1

Rapid-release formulations for administering Levo-alpha-acetylmethadol (LAAM), norLAAM and dinorLAMM and, optionally, magnesium, are provided. The formulations include solid i) core-shell oral dosage forms delivered in capsules or tablets, and ii) electrospun nano/microfiber buccal film dosage forms. Methods of the use of the formulations to treat opioid use disorder (OUD) and pain are also provided.

TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS USING NANO POLYMERS OF HISTONE DEACETYLASE INHIBITORS

Resumen de: US2025302767A1

Provided are compositions that include a histone deacetylase inhibitor (HDACi) encapsulated in and/or otherwise associated with a nanoparticle. In some embodiments, the HDACi is romidepsin, vorinostat, belinostat, panobinostat, and/or chidamide. In some embodiments, the nanoparticle is a poly(D,L-lactide)-PEG-methyl ether (mPEG-PDLLA) nanopolymer. Also provided are methods for treating diseases, disorders, and/or conditions associated with sensitivity to histone deacetylase inhibitors, such as but not limited to tumors and/or cancers; and methods for inhibiting the growth, proliferation, and/or metastasis of a tumor and/or a cancer associated with sensitivity to histone deacetylase inhibitors by administering an effective amount of a composition as disclosed herein, which methods can optionally include administering at least one additional therapeutically active agent, such as but not limited to a chemotherapeutic agent.

IMMUNE ENGINEERING AMPLIFICATION

Resumen de: US2025302763A1

This disclosure provides methods of increasing in vivo transfection efficiency and pharmacologic activity of T cells, by administering multiple small doses within a compact time period of T cell-targeted lipid nanoparticles encapsulating mRNA encoding an antigen receptor that recognizes an antigen of a cell against which immune activity is to be directed. Also provided are methods of depleting B cells, and methods of treating B cell-mediated diseases and disorders by depleting B cells and achieving immunological reset, entailing administration of immune cell-targeted lipid nanoparticles encapsulating mRNA encoding an antigen receptor recognizing a B cell marker as multiple small doses within a compact time period. The antigen receptor can be a T cell receptor or a chimeric antigen receptor.

FORMULATIONS FOR ORAL DELIVERY OF POLYPEPTIDES, ANTIBODIES AND PROTEINS AND USES THEREOF

Resumen de: US2025302766A1

Provided is a nanoparticle comprising a composition comprising a polypeptide having a molecular weight greater than 50,000 g/mol (e.g. IgY antibodies), wherein the composition is encapsulated in a material that includes a biocompatible bioerodible polymer. Also provided is a method of preparing these nanoparticles, and use of the nanoparticles as a therapeutic to treat a disease condition.

SOLID LIPID NANOPARTICLES FOR ENCAPSULATION AND DELIVERY OF BIOACTIVE COMPOUNDS AND METHODS OF MAKING THE SAME

Resumen de: US2025302764A1

Solid lipid nanoparticles (SLNs) for delivery of bioactive compounds are disclosed. The SLNs comprise a lipid matrix and surfactant layer encapsulating at least one bioactive compound selected from vitamins, minerals, enzymes, algae-derived bioactives, proteins, peptides, amino acids, antioxidants, small synthetic molecules, plant-derived volatile compounds, or botanical extracts. The SLNs exhibit submicron particle size, low polydispersity, and sufficient surface charge to ensure colloidal stability and efficient delivery. In one embodiment, algae-based bioactives, such as phycocyanin or fucoxanthin, are encapsulated using only natural and sustainable lipids and surfactants to improve bioavailability and support environmentally friendly formulations. The SLNs may be formulated for oral, topical, transdermal, injectable, ophthalmic, mucosal, textile, veterinary, or agricultural administration. Applications include human and animal health, functional foods, skincare, nutrient supplementation, and crop treatment. The disclosed SLNs offer a biocompatible and scalable delivery system that protects sensitive compounds, enables sustained release, and enhances absorption across diverse industries.

TRIACETYL ANDROGRAPHOLIDE NANOCRYSTAL AND PREPARATION METHOD AND APPLICATION THEREOF

Resumen de: US2025302765A1

The triacetyl andrographolide nanocrystal is mainly composed of triacetyl andrographolide, a stabilizer and an excipient, and an average particle size of drug particles in a triacetyl andrographolide nanocrystal suspension obtained by redissolving the triacetyl andrographolide nanocrystal in water, is less than 500 nm, and a PDI is less than 0.2. The nanocrystal suspension is prepared from the triacetyl andrographolide and the stabilizer by a high-speed shear anti-solvent method in combination with a high-pressure homogenization method, then the excipient is added, and the nanocrystal is prepared through spray-drying.

SELF-EMBEDDING SILVER NANOPARTICLE BIOMASS WASTE COMPOSITIONS

Resumen de: US2025302769A1

Compositions and methods of making and using silver nanoparticles embedded in biomass waste matrixes of various types is described. Exemplified compositions include a silver nanoparticle embedded in a cotton gin waste nanofiber composite. Compositions and methods of making and using aerogels comprising silver nanoparticles in cotton gin waste nanofiber are described. Exemplified uses of compositions include use as antimicrobial agents.

NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF

Nº publicación: US2025302762A1 02/10/2025

Solicitante:

UNIV OF CONNECTICUT [US]
University of Connecticut

Resumen de: US2025302762A1

A self-assembled nanomaterial includes a Janus base nanotube, wherein the Janus base nanotube includes at least one compound represented by Formulas I to XII, or a pharmaceutically acceptable salt thereof. Also described are compositions including the Janus base nanotubes.